-
1 month ago | 
nature.com | R. C. Coombes |Simon Lord |Zahi Mitri |Carlo Palmieri |William Gradishar |Patrick Ward | +2 more
Correction to: Nature Communications https://doi.org/10.1038/s41467-023-40061-y, published online 24 July 2023 In the version of the article initially published, there was an error in the Table 3 rows reporting progression-free survival for patients without liver metastases, which, now reading “No liver metastases (N = 17); 13.8 (7.4, NC),” appeared originally as “No liver metastases (N = 17); 11.1 (1.7, NC),” while in the row now reading “Liver metastases (N = 14); 2.8 (1.8, 7.4)” the row...
-
Jan 8, 2025 | 
jwatch.org | William Gradishar
-
Jan 3, 2025 | 
jwatch.org | William Gradishar
William J. Gradishar, MD, reviewing The selective estrogen-receptor degrader imlunestrant improved progression-free survival compared with endocrine therapy. The development of new oral selective estrogen-receptor degraders (SERDs) has increased the treatment options for metastatic ER+/HER2− breast cancer. Imlunestrant is a brain-penetrant SERD shown to have clinical activity in endocrine-refractory tumors, including those that develop ESR1 mutations. It is not yet FDA approved.
-
Nov 22, 2024 | 
jwatch.org | William Gradishar
William J. Gradishar, MD, reviewing Combining endocrine therapy with a CDK4/6 inhibitor and a PIK3CA inhibitor improves outcomes in patients with ER+/HER2− metastatic breast cancer and PIK3CA mutations.
-
Nov 1, 2024 | 
jwatch.org | William Gradishar
William J. Gradishar, MD, reviewing A meta-analysis points to the strengths of moderate hypofractionation in minimizing some acute and late adverse effects. Various radiation fractionation schedules exist in breast cancer treatment, and different clinical scenarios might make one approach more appropriate than another. Important considerations beyond efficacy are adverse effect profiles and cosmesis.
-
Oct 2, 2024 | 
jwatch.org | William Gradishar
William J. Gradishar, MD, reviewing Long-term follow-up from the KEYNOTE-522 trial shows improved overall survival with the addition of pembrolizumab compared with placebo.
-
Sep 12, 2024 | 
jwatch.org | William Gradishar
William J. Gradishar, MD, reviewing The Breast Cancer Index, which measures estrogen signaling and tumor proliferation, distinguished patients who benefited from ovarian suppression versus those who did not - and the results were unexpected. Genomic assays are used to determine which patients with early stage, estrogen-receptor-positive (ER+) breast cancer can avoid chemotherapy and to inform the duration of adjuvant endocrine therapy.
-
Sep 3, 2024 | 
jwatch.org | William Gradishar
William J. Gradishar, MD, reviewing In a large, propensity-matched, post hoc analysis, patients with invasive lobular carcinoma had higher risk for long-term recurrence and death than those with breast cancer of no special type. Invasive lobular carcinoma (ILC) is the second most common type of breast cancer after breast cancer of no special type (NST), accounting for 10% to 15% of all new cases.
-
Aug 23, 2024 | 
jwatch.org | William Gradishar
William J. Gradishar, MD, reviewing Patients showing tumor response or stable disease with chemotherapy did better when switched to molecularly targeted treatments than those who continued chemotherapy. Cancer of unknown primary (CUP) has been associated with a poor prognosis, short survival, and treatment approaches that typically utilize generic chemotherapy regimens with antitumor activity in the most likely primary sites of disease.
-
Jul 29, 2024 | 
jwatch.org | William Gradishar
William J. Gradishar, MD, reviewing In individuals carrying such variants, the lifetime risk of gastric cancer may be lower than previously thought, except in those with a strong family history of the disease.
